Cargando…

Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children

Unrelated umbilical cord blood transplantation (UCBT) is an alternative to provide transplants in children with acute leukemia or myelodysplastic syndrome who lack a related donor. Intravenous Busulfan (Bu) combined with therapeutic drug monitoring-guided dosing has been increasingly used, with more...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benadiba, Joy, Ansari, Marc, Krajinovic, Maja, Vachon, Marie-France, Duval, Michel, Teira, Pierre, Cellot, Sonia, Bittencourt, Henrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880335/ https://www.ncbi.nlm.nih.gov/pubmed/29608607 http://dx.doi.org/10.1371/journal.pone.0193862

Ejemplares similares

Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients
por: Ansari, M, et al.
Publicado: (2016)

Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
por: Bremer, Sara, et al.
Publicado: (2015)

Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation
por: Huezo-Diaz Curtis, P, et al.
Publicado: (2018)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study
por: Ben Hassine, Khalil, et al.
Publicado: (2021)

Autologous Hematopoietic Recovery after Unrelated Umbilical Cord Blood Transplantation with Myeloablative Conditioning for Acute Myelogenous Leukemia
por: Gomyo, Ayumi, et al.
Publicado: (2020)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Improved engraftment and therapeutic efficacy by human genome-edited hematopoietic stem cells with Busulfan-based myeloablation
por: Poletto, Edina, et al.
Publicado: (2022)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy
por: Ceppi, Francesco, et al.
Publicado: (2016)

Preclinical IV busulfan dose-finding study to induce reversible myeloablation in a non-human primate model
por: Mahmud, Nadim, et al.
Publicado: (2018)

Comparison of Matched Unrelated and Matched Related Donor Myeloablative Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia in First Remission
por: Walter, Roland B., et al.
Publicado: (2010)

The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation
por: Uppugunduri, Chakradhara Rao S., et al.
Publicado: (2017)

Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning
por: Wagner, John E., et al.
Publicado: (2021)

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
por: Lee, Ji Hyun, et al.
Publicado: (2010)

Unrelated Bone Marrow Transplantation with a Reduced Toxicity Myeloablative Conditioning Regimen in Wiskott-Aldrich Syndrome
por: Kang, Hyoung Jin, et al.
Publicado: (2008)

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study
por: Popat, Uday R., et al.
Publicado: (2022)

Targeting Myeloid Cells to the Brain Using Non-Myeloablative Conditioning
por: Böttcher, Chotima, et al.
Publicado: (2013)

GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study
por: Ansari, Marc, et al.
Publicado: (2017)

Non-myeloablative busulfan chimeric mouse models are less pro-inflammatory than head-shielded irradiation for studying immune cell interactions in brain tumours
por: Youshani, A. Saam, et al.
Publicado: (2019)

Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
por: Bonifazi, Francesca, et al.
Publicado: (2022)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

P1270: MYELOABLATIVE FRACTIONATED BUSULFAN-BASED CONDITIONING REGIMEN IN PATIENTS WITH AML AND MDS: RESULTS OF A RANDOMIZED CLINICAL TRIAL COMPARING 2 FRACTIONATION SCHEDULES
por: Popat, Uday R., et al.
Publicado: (2023)

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation
por: Massoud, Radwan, et al.
Publicado: (2022)

Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia
por: Byun, Ja Min, et al.
Publicado: (2020)

Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy
por: Farhan, Shatha, et al.
Publicado: (2017)

The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
por: Zhu, Shengyun, et al.
Publicado: (2021)

Correction: The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
Publicado: (2022)

IDH1 as a Cooperating Mutation in AML Arising in the Context of Shwachman-Diamond Syndrome
por: Mourad, Stéphanie, et al.
Publicado: (2019)

Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients
por: van Hoogdalem, Matthijs W., et al.
Publicado: (2020)

Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation
por: Seydoux, Claire, et al.
Publicado: (2022)

Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction
por: Al-Enezi, Bashayer F., et al.
Publicado: (2023)

Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy
por: Guidolin, Valeria, et al.
Publicado: (2023)

Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party
por: Rubio, Marie Thérèse, et al.
Publicado: (2017)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Design and Testing of an EHR-Integrated, Busulfan Pharmacokinetic Decision Support Tool for the Point-of-Care Clinician
por: Abdel-Rahman, Susan M., et al.
Publicado: (2016)

Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients
por: Salvaris, Ross, et al.
Publicado: (2022)

Pulmonary hypertension associated with busulfan
por: Hagenburg, Jean, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c90u557sbprbcnv9a00od5n8h2